Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
6.22
+0.24 (4.01%)
Mar 23, 2026, 4:00 PM EDT - Market closed
INTS's stock price has decreased by -87.56% in the past year and price targets may not have had time to catch up.
Intensity Therapeutics Analyst Ratings
Total Analysts
2
Consensus Rating
Strong Buy
Price Target
$56.25
Upside
+804.34%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Buy Maintains $100 → $38 | Buy | Maintains | $100 → $38 | +502.89% | Aug 20, 2025 |
| Brookline Capital | Brookline Capital | Hold → Strong Buy Upgrades $75 | Hold → Strong Buy | Upgrades | $75 | +1,105.79% | Aug 12, 2025 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $213 | Strong Buy | Initiates | $213 | +3,316.40% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $125 | Strong Buy | Reiterates | $125 | +1,909.65% | Nov 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $125 | Strong Buy | Initiates | $125 | +1,909.65% | Oct 31, 2024 |
| Benchmark | Benchmark | Buy Reiterates $300 | Buy | Reiterates | $300 | +4,723.15% | Jul 11, 2024 |
| Benchmark | Benchmark | Buy Reiterates $300 | Buy | Reiterates | $300 | +4,723.15% | May 16, 2024 |
| Benchmark | Benchmark | Buy Reiterates $300 | Buy | Reiterates | $300 | +4,723.15% | Mar 21, 2024 |
| Benchmark | Benchmark | Buy Reiterates $300 | Buy | Reiterates | $300 | +4,723.15% | Nov 14, 2023 |
| Benchmark | Benchmark | Buy Reiterates $300 | Buy | Reiterates | $300 | +4,723.15% | Aug 24, 2023 |
| Benchmark | Benchmark | Buy Initiates $300 | Buy | Initiates | $300 | +4,723.15% | Jul 18, 2023 |